Dec 14, 2022Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 2, 2022Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Nov 28, 2022Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Sep 21, 2022Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Aug 23, 2022Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 2, 2022Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jul 28, 2021Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits
Jun 13, 2021Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Jun 7, 2021Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73
Jun 3, 2021Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73
Mar 16, 2021Anavex Life Sciences Reports ANAVEX®2-73 featured as a Disease-Modifying Small Molecule in Trials
Aug 4, 2020Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 for Alzheimer’s
Jun 3, 2020Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73